Aide Nicolas, Allouache Djelila, Ollivier Yann, de Raucourt Sixtine, Switsers Odile, Bardet Stéphane
Nuclear Medicine Department, François Baclesse Comprehensive Cancer Centre, Caen, France.
Mol Imaging Biol. 2009 Jul-Aug;11(4):224-8. doi: 10.1007/s11307-008-0191-y. Epub 2009 Mar 31.
We aimed at investigating whether early metabolic response to corticosteroid therapy may be used as a diagnostic tool to discriminate between cancer and sarcoidosis, a well-known cause of false-positive 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET) findings in oncology.
Two cancer patients with biopsy-proven sarcoidosis or sarcoid-like reaction had multiple thoracic FDG foci. After infectious disease had been excluded, patients received oral corticosteroids for 16 and 14 days, respectively, and underwent posttherapeutic FDG-PET examination.
Posttreatment PET revealed a complete metabolic response in both patients, and clinical and imaging follow-up showed no sign of cancer progression.
Early metabolic response to systemic corticosteroid treatment may be used as a tool in the establishment of final diagnosis when sarcoidosis is suspected in a cancer patient and could be capable of differentiating cancer from sarcoidosis in the case of coexisting diseases.
我们旨在研究皮质类固醇治疗的早期代谢反应是否可作为一种诊断工具，以区分癌症和结节病，结节病是肿瘤学中导致2-脱氧-2-[F-18]氟-D-葡萄糖正电子发射断层扫描（FDG-PET）结果出现假阳性的一个众所周知的原因。
两名经活检证实患有结节病或结节样反应的癌症患者有多个胸部FDG病灶。在排除感染性疾病后，患者分别接受了16天和14天的口服皮质类固醇治疗，并进行了治疗后的FDG-PET检查。
治疗后PET显示两名患者均有完全代谢反应，临床和影像学随访均未显示癌症进展迹象。
当癌症患者疑似患有结节病时，全身皮质类固醇治疗的早期代谢反应可作为确立最终诊断的一种工具，并且在存在合并疾病的情况下，有可能区分癌症和结节病。
